866-997-4948(US-Canada Toll Free)

Squamous Cell Carcinoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 123 Pages


Global Markets Directs, \'Squamous Cell Carcinoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Squamous Cell Carcinoma.
  • A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents 

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Squamous Cell Carcinoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Squamous Cell Carcinoma 10
Squamous Cell Carcinoma Therapeutics under Development by Companies 12
Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Squamous Cell Carcinoma Therapeutics - Products under Development by Companies 19
Squamous Cell Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Squamous Cell Carcinoma Therapeutics Development 21
Boehringer Ingelheim GmbH 21
Shionogi & Co., Ltd. 22
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Novartis AG 25
Genmab A/S 26
NexMed, Inc. 27
Clinuvel Pharmaceuticals Limited 28
Oncolytics Biotech Inc. 29
Oryzon 30
Merrimack Pharmaceuticals, Inc. 31
Omeros Corporation 32
Cellceutix Corporation 33
Cannabis Science, Inc. 34
IRX Therapeutics, Inc. 35
GENEXTRA S.p.A. 36
Squamous Cell Carcinoma - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
trametinib dimethyl sulfoxide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pemetrexed disodium - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pelareorep - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
irinotecan sucrosofate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
afamelanotide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Kevetrin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
IRX-2 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
afatinib dimaleate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
nedaplatin + [docetaxel] - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
GPR87 Antagonist - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
paclitaxel - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GPR39 Antagonist - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
BXQ-350 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
boanmycin hydrochloride + [docetaxel] - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CS-TATI-1 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
mAb For Squamous Cell Cancer - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
CIGB-128 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
interleukin-15 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
DAC-0060 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CS-S/BCC-1 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TF-011-Monomethyl Auristatin E - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
AMXT-1501 + eflornithine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Allogenic Mesenchymal Stem Cells - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Squamous Cell Carcinoma Therapeutics - Drug Profile Updates 88
Squamous Cell Carcinoma Therapeutics - Discontinued Products 112
Squamous Cell Carcinoma Therapeutics - Dormant Products 113
Squamous Cell Carcinoma - Product Development Milestones 114
Featured News & Press Releases 114
Jul 02, 2013: VentiRx Pharmaceuticals Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination with Cetuximab and Chemotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 114
Jun 06, 2013: Taiho Pharma Presents Results Of Phase III Trials Of TS-1 On Patients With Colorectal Cancer And Head And Neck Cancers At ASCO 115
May 15, 2013: Synta Pharma Announces Presentations On Ganetespib Clinical Trials At 2013 ASCO Annual Meeting 116
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 117
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung 117
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 118
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 118
Jul 06, 2012: Navidea To Present Data From Lymphoseek Program At Upcoming Upcoming Scientific Meetings In July 119
Jun 02, 2012: Oncothyreon Provides Update On PX-866 Phase II Program 120
Apr 04, 2012: Berg Pharma Presents Data On BPM 31510 At AACR Meeting 2012 121

Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Table


Number of Products Under Development for Squamous Cell Carcinoma, H2 2013 10
Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Boehringer Ingelheim GmbH, H2 2013 21
Shionogi & Co., Ltd., H2 2013 22
Eli Lilly and Company, H2 2013 23
GlaxoSmithKline plc, H2 2013 24
Novartis AG, H2 2013 25
Genmab A/S, H2 2013 26
NexMed, Inc., H2 2013 27
Clinuvel Pharmaceuticals Limited, H2 2013 28
Oncolytics Biotech Inc., H2 2013 29
Oryzon, H2 2013 30
Merrimack Pharmaceuticals, Inc., H2 2013 31
Omeros Corporation, H2 2013 32
Cellceutix Corporation, H2 2013 33
Cannabis Science, Inc., H2 2013 34
IRX Therapeutics, Inc., H2 2013 35
GENEXTRA S.p.A., H2 2013 36
Assessment by Monotherapy Products, H2 2013 37
Assessment by Combination Products, H2 2013 38
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Stage and Molecule Type, H2 2013 43
Squamous Cell Carcinoma Therapeutics - Drug Profile Updates 88
Squamous Cell Carcinoma Therapeutics - Discontinued Products 112
Squamous Cell Carcinoma Therapeutics - Dormant Products 113

List of Chart


Number of Products under Development for Squamous Cell Carcinoma, H2 2013 10
Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 37
Assessment by Combination Products, H2 2013 38
Assessment by Route of Administration, H2 2013 39
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Molecule Type, H2 2013 41
Assessment by Stage and Molecule Type, H2 2013 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *